PD-L1 Expression in Non-Clear Cell Renal Cell Cancer
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in non-clear cell kidney cancer.
Clinical Pearls:
- In the past, it was thought that immune therapies worked better in clear-cell kidney cancer compared to non-clear cell kidney cancer
- A study found that non-clear cell tumors expressed PD-L1 on their tumor surface, begging the question if these patients might respond to PD-1 or PD-L1 antibodies
- Patients with non-clear cell tumors should be included in future trials that include PD-1 or PD-L1 antibodies
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
